研究者詳細 - 安藤　雄一

論文 - 安藤　雄一

分割表示 111 件中 1 - 20 件目／全件表示 >>

Ando Y, Terada T

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 41 巻 ( 22 ) 頁： 3875 - + 2023年8月

Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022

Ando, Y; Nishiyama, H; Shimodaira, H; Takano, N; Sakaida, E; Matsumoto, K; Nakanishi, K; Sakai, H; Tsukamoto, S; Komine, K; Yasuda, Y; Kato, T; Fujiwara, Y; Koyama, T; Kitamura, H; Kuwabara, T; Yonezawa, A; Okumura, Y; Yakushijin, K; Nozawa, K; Goto, H; Matsubara, T; Hoshino, J; Yanagita, M

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY 28 巻 ( 10 ) 頁： 1315 - 1332 2023年10月

A nationwide, cross-sectional, web-based survey on healthcare providers' knowledge about, attitudes toward, and perceived barriers to adherence to clinical practice guidelines for anticancer drug therapy for older patients with cancer in Japan

Matsuoka, A; Shimazu, T; Takahashi, M; Nagashima, F; Nishiyama, H; Fujimori, M; Ando, Y

JOURNAL OF GERIATRIC ONCOLOGY 14 巻 ( 1 ) 頁： 101399 2023年1月

A rapid and durable response to larotrectinib in a patient with NTRK fusion-positive secretory carcinoma originating from the external auditory canal

Ando, Y; Morita, S; Shimokata, T; Tsuzuki, T; Inafuku, S; Iwami, K; Brega, N; Akagawa, T; Tsujino, T; Ogawa, T

INTERNATIONAL CANCER CONFERENCE JOURNAL 11 巻 ( 4 ) 頁： 242 - 246 2022年10月

Outcomes of immune checkpoint inhibitor-induced liver toxicity managed by hepatologists in a multidisciplinary toxicity team.

Ito T, Mizuno K, Yamamoto T, Yasuda T, Yokoyama S, Yamamoto K, Imai N, Ishizu Y, Honda T, Hama M, Kataoka T, Shimokata T, Ando Y, Kawashima H

Hepatology research : the official journal of the Japan Society of Hepatology 2024年4月

Long-term response to MEK inhibitor monotherapy in a patient with papillary thyroid carcinoma harboring BRAFV600E mutation

Takano, Y; Shimokata, T; Urakawa, H; Kikumori, T; Ando, Y

INTERNATIONAL CANCER CONFERENCE JOURNAL 2024年4月

Durvalumab plus carboplatin-etoposide treatment in a patient with small-cell lung cancer on hemodialysis: a case report and literature review

Ushijima, F; Hase, T; Yamashita, Y; Kim, H; Shimokata, T; Kondo, C; Sato, T; Baba, T; Watanabe, S; Futamura, K; Ando, Y; Mizuno, M; Ishii, M

INTERNATIONAL CANCER CONFERENCE JOURNAL 13 巻 ( 2 ) 頁： 88 - 92 2024年4月

Efficacy and Safety of Anti-angiogenic Agents for Cancer Patients With Proteinuria or a History of Proteinuria: A Systematic Review.

Kato T, Kurasawa S, Takezawa K, Fujiwara Y, Yasuda Y, Ando Y

Anticancer research 44 巻 ( 3 ) 頁： 889 - 894 2024年3月

Genetic polymorphisms as predictive biomarkers of adverse events during preoperative chemotherapy in esophageal cancer

Liang, Y; Maeda, O; Miyata, K; Kanda, M; Sugita, S; Shimizu, D; Nishida, K; Kodera, Y; Ando, Y

CANCER CHEMOTHERAPY AND PHARMACOLOGY 93 巻 ( 2 ) 頁： 121 - 127 2024年2月

Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022 (oct, 10.1007/s10157-023-02415-0, 2022)

Yanagita, M; Muto, S; Nishiyama, H; Ando, Y; Hirata, S; Doi, K; Fujiwara, Y; Hanafusa, N; Hatta, T; Hoshino, J; Ichioka, S; Inoue, T; Ishikura, K; Kato, T; Kitamura, H; Kobayashi, Y; Koizumi, Y; Kondoh, C; Matsubara, T; Matsubara, K; Matsumoto, K; Okuda, Y; Okumura, Y; Sakaida, E; Shibagaki, Y; Shimodaira, H; Takano, N; Uchida, A; Yakushijin, K; Yamamoto, T; Yamamoto, K; Yasuda, Y; Oya, M; Okada, H; Nangaku, M; Kashihara, N

CLINICAL AND EXPERIMENTAL NEPHROLOGY 28 巻 ( 2 ) 頁： 123 - 124 2024年2月

Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022

CLINICAL AND EXPERIMENTAL NEPHROLOGY 28 巻 ( 2 ) 頁： 85 - 122 2024年2月

Protocol of a phase II study investigating the efficacy and safety of trifluridine/tipiracil plus ramucirumab as a third-line or later treatment for advanced gastric cancer

Nakanishi, K; Tanaka, C; Kanda, M; Miyata, K; Machida, N; Sakai, M; Kobayashi, D; Teramoto, H; Ishiyama, A; Sato, B; Oshima, T; Kajikawa, M; Matsushita, H; Ishigure, K; Yamashita, K; Fujitake, S; Sueoka, S; Asada, T; Shimizu, D; Sugita, S; Kuwatsuka, Y; Maeda, O; Furune, S; Murotani, K; Ando, Y; Ebata, T; Kodera, Y

NAGOYA JOURNAL OF MEDICAL SCIENCE 86 巻 ( 1 ) 頁： 43 - 51 2024年2月

Biomarkers for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors

Liang, Y; Maeda, O; Ando, Y

JAPANESE JOURNAL OF CLINICAL ONCOLOGY 54 巻 ( 4 ) 頁： 365 - 375 2024年1月

Docetaxel, cisplatin, and fluorouracil with pegfilgrastim on day 3 as neoadjuvant chemotherapy for esophageal cancer

Maeda, O; Furune, S; Kanda, M; Miyata, K; Shimizu, D; Sugita, S; Nishida, K; Ando, M; Kodera, Y; Ando, Y

CANCER MEDICINE 13 巻 ( 2 ) 頁： e6974 2024年1月

Potential drug interactions between pazopanib and proton pump inhibitors/potassium-competitive acid blockers in patients with soft tissue sarcoma

Liang, Y; Maeda, O; Shimokata, T; Yokota, K; Koike, H; Sakai, T; Ikuta, K; Urakawa, H; Nishida, Y; Akiyama, M; Ando, Y

INTERNATIONAL CANCER CONFERENCE JOURNAL 13 巻 ( 1 ) 頁： 63 - 67 2024年1月

Comment on: Carboplatin and irinotecan (CI) vs. Carboplatin and etoposide (CE) for the treatment of extended-stage small-cell lung cancer in an elderly population: A phase II/III randomized control trial

Furune, S; Ando, Y

LUNG CANCER 186 巻頁： 107416 2023年12月

Low Expectancy of Conversion Surgery with R0 Resection in Patients with CEA > 5.0 ng/mL at the Initial RECIST Evaluation for Metastatic Gastric Cancer

Nakanishi, K; Tanaka, C; Kanda, M; Miyata, K; Furukawa, K; Maeda, O; Shimizu, D; Sugita, S; Kakushima, N; Furune, S; Kawashima, H; Ando, Y; Ebata, T; Kodera, Y

CANCERS 15 巻 ( 21 ) 2023年11月

Adjustment of creatinine clearance for carboplatin dosing in Calvert's formula and clinical efficacy for lung cancer

Hatta, T; Hase, T; Hara, T; Kimura, T; Kojima, E; Abe, T; Horio, Y; Goto, Y; Ozawa, N; Yogo, N; Shibata, H; Shimokata, T; Oguri, T; Yamamoto, M; Yanagisawa, K; Ando, M; Ando, Y; Kondo, M; Ishii, M; Hasegawa, Y

CANCER MEDICINE 12 巻 ( 15 ) 頁： 15955 - 15969 2023年8月

A feasibility study of modified docetaxel, cisplatin, and capecitabine for advanced gastric cancer followed by gastrectomy

Liang, Y; Maeda, O; Miyata, K; Tanaka, C; Kanda, M; Shimizu, D; Fukaya, M; Koike, M; Kodera, Y; Ando, Y

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 2023年7月

Abdominal pain accompanied by elevated serum inflammatory markers and biliary enzymes for diagnosing immune checkpoint inhibitor-induced sclerosing cholangitis

Yamamoto, T; Mizuno, K; Ito, T; Yokoyama, S; Yamamoto, K; Imai, N; Ishizu, Y; Honda, T; Ishikawa, T; Kanamori, A; Yasuda, S; Toyoda, H; Yokota, K; Hase, T; Nishio, N; Maeda, O; Ishii, M; Sone, M; Ando, Y; Akiyama, M; Ishigami, M; Kawashima, H

INVESTIGATIONAL NEW DRUGS 41 巻 ( 3 ) 頁： 512 - 521 2023年6月

　前のページ - 次のページ　

<安藤 雄一>

論文 - 安藤 雄一

<安藤　雄一>

論文 - 安藤　雄一